JP6859275B2 - 膀胱がんの治療方法 - Google Patents

膀胱がんの治療方法 Download PDF

Info

Publication number
JP6859275B2
JP6859275B2 JP2017568016A JP2017568016A JP6859275B2 JP 6859275 B2 JP6859275 B2 JP 6859275B2 JP 2017568016 A JP2017568016 A JP 2017568016A JP 2017568016 A JP2017568016 A JP 2017568016A JP 6859275 B2 JP6859275 B2 JP 6859275B2
Authority
JP
Japan
Prior art keywords
mitomycin
liposome
prodrug
bladder cancer
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017568016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508589A5 (https=
JP2018508589A (ja
Inventor
アルベルト・ガビゾン
パトリシア・オハナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patricia Ohana
Lipomedix Pharmaceuticals Ltd
Original Assignee
Patricia Ohana
Lipomedix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patricia Ohana, Lipomedix Pharmaceuticals Ltd filed Critical Patricia Ohana
Publication of JP2018508589A publication Critical patent/JP2018508589A/ja
Publication of JP2018508589A5 publication Critical patent/JP2018508589A5/ja
Application granted granted Critical
Publication of JP6859275B2 publication Critical patent/JP6859275B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017568016A 2015-03-17 2016-03-17 膀胱がんの治療方法 Expired - Fee Related JP6859275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134328P 2015-03-17 2015-03-17
US62/134,328 2015-03-17
PCT/US2016/022909 WO2016149516A1 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020188037A Division JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Publications (3)

Publication Number Publication Date
JP2018508589A JP2018508589A (ja) 2018-03-29
JP2018508589A5 JP2018508589A5 (https=) 2019-04-25
JP6859275B2 true JP6859275B2 (ja) 2021-04-14

Family

ID=56919480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568016A Expired - Fee Related JP6859275B2 (ja) 2015-03-17 2016-03-17 膀胱がんの治療方法
JP2020188037A Withdrawn JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020188037A Withdrawn JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Country Status (5)

Country Link
US (1) US20180071253A1 (https=)
EP (1) EP3270898B1 (https=)
JP (2) JP6859275B2 (https=)
AU (1) AU2016233143B2 (https=)
WO (1) WO2016149516A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020207026A1 (en) * 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR100669053B1 (ko) 1999-04-23 2007-01-15 알자 코포레이션 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트
WO2003097647A1 (en) * 2002-05-15 2003-11-27 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2015191563A1 (en) * 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c

Also Published As

Publication number Publication date
US20180071253A1 (en) 2018-03-15
EP3270898B1 (en) 2021-05-05
AU2016233143B2 (en) 2021-03-25
EP3270898A4 (en) 2018-10-31
AU2016233143A1 (en) 2017-10-19
JP2018508589A (ja) 2018-03-29
WO2016149516A1 (en) 2016-09-22
CA2985330A1 (en) 2016-09-22
EP3270898A1 (en) 2018-01-24
JP2021035973A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
TWI866908B (zh) 用於治療肺部疾病的可吸入的緩釋組成物
KR102778887B1 (ko) 초음파역학 시술을 위한 미세거품-화학치료제 복합체
JP5570994B2 (ja) 治療薬を含有する新規な温度感受性リポソーム
KR100889139B1 (ko) 이리노테칸 제제
US20170273906A1 (en) Targeted liposomes encapsulating iron complexes and their uses
ES2333400T3 (es) Composiciones y procedimientos para tratar linfonas.
JP2011502134A5 (https=)
CN107921005A (zh) 利用纳米颗粒治疗肿瘤的组合物和方法
US20080026049A1 (en) Liposomal compositions for parenteral delivery of agents
ES2258471T3 (es) Suministro de liposomas cationicos de taxanos a vasos sanguineos angiogenicos.
JP2018530623A (ja) ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物
JP2021035973A (ja) 膀胱がんの治療方法
JP7096553B2 (ja) 上部尿路上皮癌の治療方法
US20040219204A1 (en) Method of treating angiogenic tissue growth
CA2985330C (en) Methods for the treatment of bladder cancer
WO2014184726A2 (en) Compounds and their use in therapy
TWI607766B (zh) 核酸、醫用奈米粒子組以及醫藥組合物
KR20240037264A (ko) Bcl 억제제의 리포솜 제형
Bölükbaş Development of novel nanoparticle-based therapeutics for treatment of lung cancer
HK40097901A (zh) 用於递送抗癌剂的具有改进的治疗指数的组合物和方法
HK40043569B (zh) 用於治疗肺部疾病的可吸入脂质体缓释组合物
ZA200505740B (en) Method of treating angiogenic tissue growth

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201111

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210127

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210325

R150 Certificate of patent or registration of utility model

Ref document number: 6859275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees